



Verification of precision and bias

Elvar Theodorsson

Validation and verification of measurement methods

 Procedures aiming at establishing realistic expectations with the analyst and confidence with the end-user that the methods are fit for the intended purposes

Validation

- According to VIM 3, verification is "provision of objective evidence that a given item fulfills specified requirements" and
- Validation is "verification, where the specified requirements are adequate for the intended use"



Method validation

- Method validation is a specific kind of validation "the process of defining an analytical requirement, and confirming that the method under consideration has performance capabilities consistent with what the application requires"
- Method validation includes procedures that both 1) establish the performance characteristics and limitations of a measurement method (e.g., trueness, precision, recovery, linearity, robustness) and 2) establish whether the performance characteristics of the measurement method being investigated are fit for the intended purpose

Method verification

- Procedures to test to what extent the performance data obtained by manufacturers during method validation can be reproduced in the environments of end-users
- Possible if the method (reagents, procedure and the measurement instrument) is manufactured by a company or other reliable source which has performed proper method validation and who is providing you with the detailed results, a single laboratory method validation is not needed.

Method validation is performed to a varying extent depending on its intended use

- Single laboratory method validation is appropriate where the method is used for a specific purpose in a specific laboratory by personnel with the appropriate training.
- Full method validation includes, in addition to the procedures employed in single laboratory validation an interlaboratory study (collaborative study/ collaborative trial) with many measurement instruments several operators etc. The performance characteristics of the measurement method over extended periods of time are also studied in full method validation, including the effects of lot-to-lot variation etc.
- Full diagnostic method validation is establishing the diagnostic properties of the method e.g. in health and disease

Verification of measurement methods

- In Vitro Diagnostic (IVD) medical devices are in Europe regulated by a third EC Medical Device Directive, the IVD medical device Directive 98/79/EC which has been mandatory in Europa since December 2003
- Local verification practices have commonly been established over time and are frequently influenced by accreditation and certification authorities. Published practices for end-user verification officially endorsed both by the end-users and by the companies have appeared only recently

Verification

The EP15-A2 protocol from CLSI

- Uses control material with assigned concentration (e g from external quality control) or certified reference materials
- Does not test for matrix effects which may occur in patient materials
- Practical and pragmatic method **using patient samples** and common samples for internal quality control
 - Bias is tested by comparison with a well-established methods using at least 20 patient samples
 - Variation within- and between series is measured using the normally used stable materials for internal quality control at least twice daily during two weeks



EP15-A2 Vol. 25 No. 17 Replaces EP15-A Vol. 21 No. 25

User Verification of Performance for Precision and Trueness; Approved Guideline—Second Edition

NOTE—The following sections were corrected editorially in April 2006: Sections 8.6, 9.1, 9.2.2 and 9.2.4; and Appendixes B, D, E, F, G, and H.

This document describes the demonstration of method precision and trueness for clinical laboratory quantitative methods utilizing a protocol designed to be completed within five working days or less.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.



(Formerly NCCLS)

http://www.clsi.org/source/ orders/free/ep15a2f.pdf

Verification of measurement methods

- Clinical laboratories commonly measure in the order of 20 to 200 natural patient samples having as wide concentration range as possible, using both the method being replaced and the new method. At least two pooled patient samples may also be used, and this may actually be an advantage when the medical decision point is close to the detection limit of the method.
- Suitable stable materials for internal quality control are measured at two levels in at least three replicates for at least five consecutive days but preferably at least two weeks for estimating imprecision and for establishing initial control limits for the internal quality control procedures. Linear regression, bias-plot and analysis of variance techniques are used to determine bias, imprecision, matrix effects

Measurement precision/imprecision

- Closeness between indications or measured quantity values obtained by replicate measurements on the same or similar objects under the specified conditions of measurement
- The quantitative expression of precision is the standard deviation (SD) or relative standard deviation (CV/CV %)
- The standard deviation of the estimate of the standard deviation is inversely proportional to the square root of the number of replicates

Harmonised terminology – VIM 3





Repeatability imprecision

- When the same measurement procedure, same operators, same measuring system, same operating conditions and same location, and replicate measurements on the same or similar objects over a short period of time
- A short period of time is usually less than a working day of 8 hours
- Example of repeatability condition is when a stable control material or the same unknown sample is measured repeatedly on the same day
- A prudent and cost effective number of replicate measurements for estimating repeatability imprecision are in the order of 15

Intermediate measurement precision

- When a set of conditions that includes the same measurement procedure, same location, and replicate measurements on the same or similar objects over an extended period of time, but may include other conditions involving changes
- Intermediate measurement imprecision includes variation due to new calibrations, new reagent lots, new operators etc.
- The concept of between-days, between series, inter-series imprecision has earlier been used to describe this type of imprecision

Intermediate measurement precision

- Intermediate imprecision is usually measured using stable control materials in two different concentrations which are measured routinely/daily over extended periods of time for at least 1 year, but preferably during 2-3 years
- It is crucial that all sources of variation included in intermediate imprecision including e.g. lot-number changes are included in sufficient/appropriate number of occurrences

Intermediate and repeatability precision

 If the numbers of results obtained in each series/day are the same, common two-way analysis of variance (ANOVA) can be used to calculate the total SD and its components of SD within and between series. However, as is commonly the case in clinical laboratories, the number of replicate observations in the series is unequal, more advanced ANOVA and variance component analysis models catering for unequal number of observations each day/series should be used

Fishbone/cause and effect/lschikawa diagram



Measurement bias

- Bias in the preparation of the calibrator, including erroneous volume measurements or weighing of calibrators
- Using sample matrix for the calibrators which differs from the matrix in the samples
- Interferences/matrix effects in the samples, e.g. the colour of bilirubin and haemoglobin in icteric and haemolytic samples in laboratory medicine or the presence of high concentrations of lipids or proteins in the sample (hyperlipidaemia or myeloma). Manufacturers commonly use samples from healthy subjects for their validation studies, and the real influence of matrix effects on the methods may be fully evident only when the methods are fully introduced in diagnosing and monitoring seriously ill patients.

Measurement bias

- The presence of molecules in the sample specifically interfering with the reagents used in the measurement process, e.g. heterophilic antibodies (e.g. human antibodies against mouse IgG frequently used in immunoassays).
- Uncorrected loss of measurand at extraction
- Instability of the sample during transport or storage

Determining measurement bias

- Purchasing certified reference materials from companies or organizations of high metrological competence and comparing the stated concentration with the concentration your own methods shows
- Comparing the concentrations your method measured in natural samples with the concentrations a reference method measured in the same sample
- Participating in programs for external quality control. Most of these programs are based on consensus concentrations in modified control samples, but some few are based on comparison to reference methods. The latter are frequently preferable.

Determining measurement bias

- Measuring the recovery of the measurand in spiked natural samples
- Comparing the serial dilution of a natural sample or that of a spiked natural sample with the serial dilution of the calibrator in the calibration curve

Determining measurement bias

- Making studies of possible interferences/selectivity.
- This is evidently very different amongst different measurement methods and fields of study. In laboratory medicine the studies of interferences by bilirubin, haemoglobin, lipids, proteins and drugs are amongst the most important. VIM 3 defines selectivity as "property of a measuring system, used with a specified measurement procedure, whereby it provides measured quantity values for one or more measurands such that the values of each measurand are independent of other measurands or other quantities in the phenomenon, body, or substance being investigated"

Common linear regression



Orthogonal linear regression



Adcock (1878) = Deming (1943) Passing Babloc (1988) Bartlett (1949)



Bias plot Mean difference plot (Tukey, 1977) Eksborg (1981) Bland-Altman (1983)

Beware of the use of the correlation coefficient

 Any correlation coefficient between two methods can be improved (made closer to 1) by increasing the range of concentrations measured.

A conglomerate of laboratories

 In healthcare, the samples from a patient are over time likely to be measured in different laboratories using different methods as the patient visits primary care and different levels of hospital care.





Show Details 🔎			1							Silicon and a single of	Billion Conservation
Patient Samples	and and a summary line	and the state of t	Manager of Manager and Manager of Street or other	and the second s	and the second second line	and a supervision of the last spin states of the last	Mandan Second Stifters	and and a first of the Hart of the second se	and a design of the second sec		And Second Self.
the second second											
aners	241 AM	2011 PPI	3411 PPI	2011 PPI	28-11 PP	2118 PPI	2811 PRI Conclusion D-Crystocolory, purpersoner I	Sall bai	4011 PFI	401 PPI	408 PPI
2011-11-16			E								
^				and good a spectra good g		Male Advergalition and	southerstations and the			and a second	L.S
50 C											
ker 🖉	EPK (1923 B Erytracytor, partituliana, (EPE [1103 B-Espiracytor, partilelisme.]	EPC (100 B-Erginosytes, particilions.)	EPK (2023 B-Erprocetor, partiladione.	EPE (1933) Rolleytrocyter, puttheliume.	EPK (1905 B-Esytempter, partitelione,)	(SPK [TES B-Expression, particulions.]	EPR (1923 B-Erpirnepter, partilalisme.	(FPE [1103 B-Esylesceptor, purificiliane,	(EPK [100 B-flowroughts, particilions.)	(EPK (2015 B-Expression, 5200 241
				ere m	Anya PPT	-		Cara Pri			Name PP1
	ag-games - so-magong	Age-aggleregited and an appropriate states	a manual property and the	And age of the state of the sta	Partitili construction of a participation of the state of the	ange land and a star			and the second s	and the second s	
*											
	EPK (1905 B-Erytrocytor, purilishanc.)	EPE [100 B-Especoptar, pursileakone.	EPK 1100 B-Erytrocytes, partikelikose. (EPK (1885 B-Erytrocyce, gortikalizes:	EPK (1909 B-Exproceptor, purchallione.	EPE (100 B-Erytrocyter, partilelikosc.)	(DRI (1988 D-Gryssogius, partikulikost.)	EPK (1903 B-Erptrocytor, porsibalismic	EPE (1909 B-Espholiptur, purillelikose.	(EPK (100 B-Erymocytos, partikulkosc.	EPK (1988 B-Erytracytos, 1
Control Protein I	628 191	Kerr PPI	6210 PPI	6215 111	100 PPI	NUT PPI	5211 PP1	100 100	851 PH	4610 PP1	8111 144
H Control Protein	6		Contraction of the State of the				and the second second	CARLON COURSES			State State States
Control Protein			and the second se	LILL THREE BOARD						Contraction and an and a second	
ntrol Protein U	FPR 1983 E. Pretransfer marilelynes (EVERTER R. Extended and advantage	FVF (1917 B. Sectore sites and advantage)	FVF HIGH R Protocology and maintaining	EVE TID! & Entransis submitted	EVERAL Reflectionality asheetishing	EVE UNIT Million states and an individual	EVE ITAL R. Frainanter, submittability	EVERTHER R. Endowed an and an including	FVF (1917 B-Southeaster asheeftedding	EVE HALL B. Contraction .
Inivit1	636 Hi	Sele PP	Jets pp	544 441	Sdie wei	Sain PPI	500 - FPI	56.0 Mi	Ster PPI	30H HA	2215 141
nivă 2	Contraction of the second second	State of the second	and the second se	Annual Contractory of the second second	Lands of the second second second	in the second			Manager and the second s	Real and the second second	Electronic and the
nWå T	and a sub-sub-sub-		and the second second second		Supervision and state	and and an and a statement		Marthurson and a second se	Mada. Astrones, all boosta	- the first of a stand of	
ea kontroll											
Hog	401 PPI	400 PPI	495 PF1	418 PPI	458 PPI	4411 PPI	4512 PP1	5202 PPI	6210 PPI	8211 PP1	6212 PPI
Lag									**	1	[
Nomal		aged - house to have a	Automatic in what the fight			I manually sugar states	and did inspected		sand a past state adada.		
110, 150											
Tiol, hog	EVF (1107 B-Explorection, voluminalities	EVP CEEP B-Exproceptur, solyminalities	EVV [101 B-Environyites, solymiralition, \$255 PP1	EVF [110] B Environmenter, voluminalities	EV# (1100 B-Exploreptor, valgestrabilities	EVF DBDF B-Enstrocator, solparitation	EVF [100] B-Erstracetor, rolandituition	EVF (100) B-Erytrocytor, voluminalities	EVF CROP B-Exploseptor, volpminulation	EVF [1907 B-Enginecytor, noiseainshiton	CAT DIGT B-Expression, a
skontol.Seron					And the owner want to be a second sec	_	state and state and states				E E
n kontol Seioni		Name of Street o									
entkontralLLMC		and the second	and the second se								1
nunoassay, prog	EVF (1101 B-Erytaucetur, volgestraistics	EVF (1927 D-Esytrocytes, volymbridding	EVF (1907 E-Grywoogter, solyadrolytics	EVF (1107 B-Ergencepter, volgestruktion	JF4 (1240 F-JG4)	of a (1240 P-Jim)	Fib (P-Fibriogen)	Fib (P-Fibrinogen)	QQT (1226 P-Y-Qhitseyknastorur)	GGT [1224 P-Y-Glutang/transform)	GGT (1224 P-Y-Glatungh
emedel	8511 PPI	SEII PPI	4714 PP1	05H PPI	1205 PPI	7206 PPI	000 PPI	001 891	225 PPI	2500 PP1	254 391
emedel	-						Statement of the local division of the local				
emedei											
smedel	GET FERRE D.Y. Chromobile structured	OCT 19254 B.T. Christian Arrest	OCT 11234 B.V. Changeling days	COT FERA E.V. Obtandena danal	OUT DOM IN Change and sectored	DOT HARA & C. Chatman Street Street	OCT 1924 B.V.Chandrenford	OUT (1924 D.Y. Gistanders dural)	OUT DEER B.V. Chine American	COT 19254 S. T. Chimadhundred	CAT FIRST P.V. Cheve dry
lanon	2103 PPI	SEES PPI	4483 PPI	6600 PPI	6601 PPI	6601 PP1	stati PPI	6601 PPI	6606 PPI	6623 PPI	1201 PPI
lation				and a second sec		Second Second Second Second Second			S		
Asion .											
agusation									E		
delanalani	GGT (1224 P-T-Ghitungeruncheruc) 1205 PPI	(GGT [1224 P-1-Gutamphraethora)) 8603 PPI	2500 PF1	PGbb [1233 P-Gbbox (Turtunda)) 254 PPI	PGtat (1520) P-Gates (fastade)] 1205 PPI	PEdiak (1923) P-Ghakasi (Pastanda)) 7206 PPI	Gast-rd [rd-Gases] 8900 PP1	Gbb-vB (vB-Gbbox) 6506 991	44.51 PPI	4585 PP1	2454 PPI
ndokrimilari											distant and some
holer		Long Rallaffallan Ballin R	auf fin in belle bestannt				ageliated and a set of the set of	a-mailing Shading Same		all sealing the second se	
sansterin									-		
einenekseri spi	Hb (1905 B-Hb (Hune globia)2 2455 PM	16-[103_5-16-[%.ex-globin]] 3011 PPI	#6 [108 E-#6[Honoglobie]] 3371 PF1	Hb (1996 B-Hb)(Humoglobia)) 3471 FFI	Hb (1905 B-Hb (Runoglabia)) 3511 APR	Hb [1105 S-Hb[Hosoglobis]] 3811 PPI	Hb [100 B-Hb(Honoglobie)] 3111 FFI	Hb (1995 B Hb (Humoglobin))	Hb [1005 B-Hb [Kumoglobin]] 3301 PPI	4011 FF1	Hb [1908 B-Hb(Hunogleb) 407 PPI
ores			second second second		-				**		
ores	Station of the local division of the local d			and share the second second	all all all a subserves and	antill	Barthold and the second strategy of the	AND IN TRACTORY AND ADDR	Lough Substants	"Bulldell" brade-bedge-	and the second division of the second divisio
es											
enatologi	Hb (1938 D-Hb (Humaginbia)2	Ha [1900 B-Ha [Remoglobin]]	Mb [100 2-Mb[Hosoplobic]]	Ho (708 E-Ho(bengicka))	Http://1000_0-10-(Romorginition)\$	Hb (1100 B-Hb)H-mostokin()	(in (100: 0-Re(Henergickie)) (200: pb)	Hb (200 B-Hb (Homoglobia))	Ha (1900 D-Ha (Non-globin))	Rh [100: E-Rh(Humoplekin]]	He (200 B-He)Hanagicka
ue			in m			the Pri				544 MI	100 TF1
.581 .		THE PART OF A PARTY OF A PARTY	and approximation	Age-gaggagagaganagantgagitag		the management of the	A		Care a lidge group of these		
kemi A	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1	and the fact the second second		No. of Concession, Name				11	2	
lation	Hb (1855 B-Hb (Humogladin))	th [1105_B-th [fue oglobin]]	The [1100 S-Malffum oglobile]]	Hb (1998 B-Hb(Hunoglobia))	Hb (1905 _ B-Hb (Munoglabin))	HE (1908 S-HE(Homoglobin))	Ho (1906 _ 8-Ho(Honoglobia))	Hb (1995 B-Hb (Humo-picbia))	Hb (1935 B-Hb (Runoglabin))	No (1906 E-Mb(Homoglobie))	Hb [106 B-Hb(Hunogloba
lation .	6214 PM	428 PH	4210 111	6212 111	629 201	6219 (191	100 111	150 PP	103	8211 111	8370 (191
tein									S		
atein			alle annegaliste								
n iuin, lägni	In Party Ball (Bandaland	In Party P. M. Party of South	an inter the section of the lit	In Party Ball Observables VI	Can be be the state of the second	1000 435 08 (E) 48 431 (Ed.) 1 10	The statement of the statement of	-746-11, 100-001-00, 11, 154-1-1 TO	ARL 13 (20/00/10/11/00/10/10)	-Other Designation and the second	The statement of the
n	1991	DEN PPI	dini per	028 FP1	2404 991	1510 PPI	3670 PP1	STIC PPI	Seco PPI	3875 PP1	4110 FPI
ighter			-	C							
in in											
+ Hamacyste						L				L	/
pulation, spe	aDHbAik [Hb(Bj-HbAik [Mone Sj] 4310 PH	4470 PH	x046Alc (Hb(5)-46Alc (Meao 0)) \$382 FPI	sOPEAR [B6(B)-HEAR [Mone 1]] 6383 FFI	sOftbArk [Hb(B]-HbArk [Moso 5]] 6385 PM	IORBAIc (Hb(B)-HbAic (Moso 5)) 8388 PPI	x0HbAlic [Hb[5]-HbAlic [Maso 9][5355 FFI	SOMDAIC IND(0)-HDAIC (Mone S)]	stro PH	x0HbAlc(Hb(5)-HbAlc(Moso 0)) 8210 PFI	SOMBAIC INDIGI-HEARCIM
gulation, spe			F								
adel											
edel	and the second se		2							-	
	wDHaAts [His(B]-HaAts [Missor 2]]	ACREATE DIR(B) HEATE (Mono II)	villete.Ale (He/B) HeAle (Mono 2)0	will Hard and Bill Hard (Manar 2)	AND A REPORT OF A	ERLANDF DE HEASt (FCC) pr.)	BORATEF (BHEATE (FOC) pr)	PHEADIF IN-HEAD PECCI PH	HOLKel DO28 P-HDL-Kelestorel	HDLKs1[1223 P-HDL-Kolestoral]	HERE A TRUE PHOT - KAN
	and the		NOV PR	and the	1000 PM	and PPI	and PPI	and the	prost and and and and and		Seco Ph
ins screening	And the second second second second		and a second second								(<u></u>
os sessenine		Reality where a		1000 0000 00	and the second second	Carlos and a second		1000 - 10 K - 10 K			
the observes of the		HDLKeinges P.St. Kelener	HDUKAI D228 P.HTL Kelenard	VIDLEN 19220 P.HDL Enhanced	HOLKAPISSE P.HDL & durant	HDUKel0228 Petro Kolonius	xEDLK of 11226 (P-HC) - External 1	MDDKei (1226 P-MDL-Extension)	HOLKSI DERE PHOL Kalutaren	HDUKelliggs Parts Kelenust	WELK of 19205 P. HTL F. C.
ns screening	28 CLK of TROOD PAPER ADDRESS	the second se	The second secon	AND AND AND A SHORE AND	RADE DOL	BAUT DOL	AAOS DEL	6603 201	1207 801	1206. 001	8803 881
ns screening	4405 PP	6600 PPI	8601 PP1	0000 PP1	And the		44464			tare required to the second se	weeks the
whis screening in	ATOMA (1020 P-101-Konutorol)	6600 PM	eson PPI	9000 HH							

Land Land	inc.	CallD	Mann	Chitatali	Claranti	Clarrort	0.01	
MIC	linst	COID	Mean	CVtotar%	Cvireat%	CVerror%	70CV	- 11
M1	2454	PPI	336,3	2,658	2,086	1,804	2,325	7
M1	2455	PPI	335,1	3,126	0,7115	3,180	4,963	1
M1	3111	PPI	350,8	4,719	2,319	4,222	4,214	2
M1	3311	PPI	332.5	3.546	2.992	1.946	2.042	2

A fact stolkerst Without a Management	SData Analysis		
Andreas Tarton Catton 2014/05-01 (% to 2012/01/11/15) According 10 Sand 10 Sand	The Left Scenario Control Scenario Contr	in Jarfag Kons 100 Lastag Yan Polodi 7407 Ilani Vont Yan Ilani Mag di	447-4110010420 *
in Left in Decay Unit Al south	Coli: Avanue Statutori B. MORC 2011/001/00 00 2011/001/00 00	Adv. Chinesettis. Colin. H 8 2,144 1,255 7 H 6 0,177 1,000 4,661 1,2 6 0,177 1,000 4,661 1,2 6 1,712 1,000 4,661 1,2 6 1,142 1,244 3,1 1,4	
Depresent Orate	a Tantar at 1 101 101 101 227,0 2,0	2 8,1156 2,122 3,131 18 6 1,541 2,007 1,564 16	
Image: Control Co	Bits Distance Dist Dist <thdist< th=""> <thdist< th=""> <thdist< th=""> <t< td=""><td>1 1.44 2.44 1.</td><td></td></t<></thdist<></thdist<></thdist<>	1 1.44 2.44 1.	
E (34) - 44-556 E (34) - 323 - 100 + 100 pcd E (34) - 45-556 E (32) - 45-56 E (32) - 45-56 E (32) - 45-56 E (32) - 423 - 55-66866 E (32) - 423 - 55-6686 E (32) - 55-668 E (32) - 55-668 E (32) - 55-668 E (32) - 55-668 E (32) - 55-66 E (32) - 55-66	4212041 Units upwerg 511 PF 01.4 1 521 521 PF 01.4 1 52 521 PF 01.4 1 52 521 PF 01.4 1 52 521 PF 01.4 1 5	0.12 0.04 0.012 10 0.13 0.044 0.012 11 0.23 0.010 0.010 12 0.12 0.02 0.010 12 0.12 0.02 0.010 12 0.14 0.02 0.010 12 0.14 0.02 0.010 12 0.14 0.02 0.010 12 0.14 0.02 0.010 12 0.14 0.02 0.010 12	50 2010-14.3M



Full diagnostic method validation

	Partic			
	With disease	Without disease		
Positive test	True positives	False positives (type I error)	Total positive	[PPV]
Negative test	False negatives (type II error)	True negatives	Total negative	[NPV]
	Total with diease	Total without diease		
	[Sensitivity]	[Specificity]		

Table 1. Definition and calculation of parameters/concepts describing diagnostic properties of measurement methods.

Parameter/concept	Formula/explanation
Diagnostic sensitivity is the proportion of those with disease who have positive test results	$Sensitivity = \frac{Number of true positives}{Total with disease}$
Diagnostic specificity is the proportion of those without disease who have negative test results	$Specificity = \frac{Number of true negatives}{Total without disease}$
The positive likelihood ratio is the ratio of the true-positive to the false-positive rate	$LR + = \frac{Sensitivity}{1 - Specificity}$
The negative likelihood ratio is the ratio of the false-negative rate to the true-negative rate	$LR -= \frac{1 - Sensitivity}{Specificity}$
DOR combines the concepts of sensitivity, specificity and likelihood ratios into a single number, this is particularly useful for combining study results in systematic reviews	DOR = LR + LR -
ROC curves	ROC curves show diagnostic properties of a measurement method used to classify persons with or without disease as the decision limit between health and disease is changed
PPV is the proportion of those with a positive test result who have the disease; takes into account the prevalence of disease in the target population	$PPV = \frac{Number of true positives}{Total number of positives}$
NPV is the proportion of those with negative test results who do not have the disease; takes into account the prevalence of disease in the target population	$NPV = \frac{Number of true negatives}{Total number of negatives}$
It should be noted that the prevalence of disease in the intended population is cr DOR: Diagnostic odds ratio; NPV: Negative predictive value; PPV: Positive predict	ucial for the predictive values, but not for the other parameters. ive value; ROC: Receiver operating characteristic.

For rebrint orders, blease contact rebrints@future-science.com

Validation and verification of measurement methods in clinical chemistry

The present overview of validation and verification procedures in clinical chemistry focuses on the use of harmonized concepts and nomenclature, fitness-for-purpose evaluations and procedures for minimizing overall measurement and diagnostic uncertainty. The need for mutually accepted validation procedures in all fields of bioanalysis becomes obvious when they implement international accreditation and certification standards or their equivalents. The guide on bioanalytical method validation published by the US FDA in 2001 represents a sensible compromise between thoroughness and cost-effectiveness. Lacking comprehensive international agreements in the field, this document has also been successfully adapted in other fields of bioanalysis. European and international efforts aiming for consensus in the entire field of bioanalysis are currently being made. Manufacturers of highly automated in vitro diagnostic methods provide the majority of measurement methods used in unmodified in clinical chemistry. Validated by the manufacturers for their intended use and fitness-for-purpose, they need to be verified in the circumstances of the end-users. As yet, there is unfortunately no general agreement on the extent of the verification procedures needed.

Validation and verification of measurement methods are procedures that aim to establish realistic expectations with the analyst and confidence with the end-user that the methods are fit for their intended purposes. Different fields of bioanalysis have historically lacked a common theoretical and practical ground due not only to differences in the tasks at hand, but also to differences in terminology and in calibration, validation and quality control practices. Recent harmonization efforts in these areas [1,101,102] confirm that all fields of bioanalysis can share the same principles and nomenclature catering for extensive harmonization of guidelines, standards and practices.

In the early 1990s, the US FDA initiated and supported conferences and harmonization work on bioanalytical method validation [2,3] that, in 2001, resulted in the 'FDA Guidance for Industry - Bioanalytical Method Validation' guidelines [4,101]. They have been widely used, being suitable not only for the needs of the pharmaceutical industry but also for bioanalytical methods in general [4]. In fact, lacking similar international guidelines, this FDA document is widely used as standard reference for validation of bioanalytical measurement methods. European efforts in the field of validation (European Medicines Agency's Guidelines on Validation of Bioanalytical Methods) [5] are manufacturer's performance claims. currently in progress.

The pharmaceutical industry has been and is still a driving force in the development of validation practices given the regulatory environment they have been subject to early on. Clinical laboratories are increasingly being accredited or certified according to ISO 17025, ISO 15189 or other similar quality systems. These laboratories are therefore in need of generally accepted and costeffective protocols for validation. Theoretically, there are no limits to the extent of validation and verification procedures. However, in practice, there are time and economic constraints. It is therefore crucial that validation and verification efforts are optimized in order to maximize the value gained for the resources spent.

This brief overview of validation and verification methodologies in clinical chemistry attempts to adhere to the currently accepted guidelines in terminology and bioanalytical validation methodologies. The probable overemphasis on certain aspects, for example, on verification procedures and fitness-for-purpose investigations, may be explained by the authors' background in laboratory medicine and basic research. The current already extensive and increasing use of commercially available measurement instruments and methods underscores the need for agreement on reasonable, but sufficient, methods for end-user verification of the FUTURE

Elvar Theodorsson Clinical Chemistry, Department of Clinical & Experimental Medicine, Faculty of Health Sciences, Linköping University, County Council of Östergötland, Linköping Sweden Author for corresponde Tel.: +46 1328 6720 Fax: +46 1010 33240 E-mail: elvar.theodorsson@liu.se

http://www.future-science.com/doi/pdf/10.4155/bio.11.311



ISSN 1757-6180

What level on the measurement scale is used when quantifying precision?

A. Nominal

B. Ordinal

0%

C. Interval

0%

D. Ratio

0%

Validation should be used instead of verification when...

- A. Applying the method on a new measurement system 0%
- B. When a new technician is engaged0%
- C. When the method is modified
- D. When the control material shows out of control condition 0%

Take a home message

Verification of precision and bias

- In Vitro Diagnostic (IVD) medical devices are in Europe regulated by a third EC Medical Device Directive, the IVD medical device Directive 98/79/EC which has been mandatory in Europa since December 2003
- Local verification practices have commonly been established over time and are frequently influenced by accreditation and certification authorities. Published practices for end-user verification officially endorsed both by the end-users and by the companies have appeared only recently including the EP15-A2 protocol from CLSI.
- Practical and pragmatic method using patient samples and common samples for internal quality control.
 - Bias is tested by comparison with a well-established methods using at least 20 patient samples
 - Variation within- and between series is measured using the normally used stable materials for internal quality control at least twice daily during two weeks